UW Health weighs in on promising Alzheimer’s drug

The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass.  Shares of Biogen...
The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday, Sept. 28, 2022, after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s(AP Photo/Steven Senne, File)
Published: Sep. 28, 2022 at 8:02 PM CDT
Email This Link
Share on Pinterest
Share on LinkedIn

MADISON, Wis. (WMTV) - A new drug has been proven to help cognitive function in those with early dementia, it was announced Wednesday.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.

“I think this study has a ripple effect in that it’s encouraging for people who already have mild cognitive impairment and dementia, and I think it’s even more encouraging in that, we are already studying this medication for hopefully the first prevention of dementia,” Wisconsin Alzheimer’s Institute’s Dr. Cindy Carlsson said.

UW Health announced last year that it would be a clinical trial site for studying the same medication for the prevention of Alzheimer’s.

The director of the Alzheimer’s Institute at UW’s School of Medicine and Public Health said this is an exciting step toward finding a cure.

Officials said it they are still actively enrolling people in the study and they are in need of volunteers.